首页> 外文期刊>Expert opinion on biological therapy >Allogeneic cell therapy manufacturing: process development technologies and facility design options
【24h】

Allogeneic cell therapy manufacturing: process development technologies and facility design options

机译:同种异体细胞疗法制造:工艺开发技术和设施设计选项

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Currently, promising outcomes from clinical trials of allogeneic cells, especially allogeneic mesenchymal stromal cells, fibroblasts, keratinocytes, and human cardiac stem cells, have encouraged research institutions, small and medium enterprises (SMEs), and big pharmaceutical companies to invest and focus on developing allogeneic cell therapy products. Commercial and large-scale production of allogeneic cell therapy products requires unique capabilities to develop technologies that generate safe and effective allogeneic cells/cell lines and their fully characterized master/working banks. In addition, it is necessary to design robust upstream and downstream manufacturing processes, and establish integrated, well-designed manufacturing facilities to produce high quality affordable products in accordance with current GMP regulations for the production of cell therapy products.Areas covered: The authors highlight: the recent advances in the development of allogeneic products, the available options to develop robust manufacturing processes, and facility design considerations.Expert opinion: Currently, there are multiple challenges in development of allogeneic cell therapy products. Indeed, the field is still in its infancy; with technologies and regulations still under development, as is our understanding of the mechanisms of action in the body and their interaction with the host immune system. Their characterization and testing is also an emerging and very complex area.
机译:简介:目前,来自同种异体细胞的临床试验的有希望的结果,特别是同种异体间充质基质细胞,成纤维细胞,角质形成细胞和人心脏干细胞,鼓励研究机构,中小企业(中小企业)和大型制药公司投资和焦点在开发同种异体细胞疗法上。同种异体细胞疗法产品的商业和大规模生产需要独特的能力来开发产生安全有效的同种异体细胞/细胞系的技术及其完全表征的主/工作组。此外,还有必要设计高压上游和下游制造工艺,并建立综合,精心设计的制造工具,根据当前的GMP规定生产高质量的实惠产品,用于生产细胞疗法产品。覆盖:作者突出了:各种产品开发的最新进展,可行的制造工艺的可用选择,以及设施设计考虑因素。普遍认为:目前,同种异体细胞治疗产品的发展存​​在多种挑战。实际上,该领域仍处于起步阶段;随着技术和法规仍在开发中,我们对身体行动机制及其与宿主免疫系统的互动的理解。他们的表征和测试也是一种新兴和非常复杂的地区。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号